clinical trial · NCT07701993
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Metabolic Dysfunction-associated SteatohepatitisEfimosfermin alfaPlacebo
brief summary
This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.
started
Jul 20, 2026
primary completion
Jul 25, 2033
completion
Aug 22, 2033
last updated
Jul 14, 2026
official title
A Phase 3, Double-blind, Randomized, Placebo Controlled, 2-arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Injection in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (NEBULA-1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol